Jenburkt Pharmaceuticals Ltd. (JENBURPH) Share Price Falls 9.28% in Early Trade

Jenburkt Pharmaceuticals Ltd. traded at Rs 1030.3, down 9.28% today, with a market capitalisation of Rs 501.2 crore in early BSE trade.

Jenburkt Pharmaceuticals Ltd. Share Price came under pressure in early trade on 07 August 2026, with the stock falling to Rs 1030.3 from the previous close of Rs 1135.65. The day’s move translated into a decline of Rs 105.35, or 9.28%, and brought the company’s market capitalisation to Rs 501.2 crore. For investors tracking Jenburkt Pharmaceuticals Ltd. Share Price Today, the move stood out because it pushed the stock into the market’s top decliner list in the early session.

The available data confirms the price fall and the intensity of the early selling, but it does not establish a company-specific catalyst behind the move. That distinction matters. In stock analysis, a sharp same-day decline can reflect stock-specific news, broader market decline, liquidity conditions, or simple price action. Here, the verified information supports the fact of the fall, the trading range, the turnover and the valuation backdrop, while leaving the immediate trigger open.

Jenburkt Pharmaceuticals Ltd. Stock News is therefore being driven by the price event itself. The stock opened at Rs 1090, touched a day high of Rs 1090 and then slipped to a day low of Rs 1027.3, showing that pressure emerged quickly after the open. Univest notes that when a stock opens at its intraday high and then moves lower, traders often read that as early selling pressure rather than broad intraday recovery. Beyond the tape, investors will likely monitor valuation, profitability and how the company compares with other Pharmaceuticals & Drugs names in the Healthcare space. That wider context is important before drawing conclusions from a single session.

Jenburkt Pharmaceuticals Ltd. (JENBURPH) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,030.3
Previous Close	Rs 1,135.65
Today's Change	Rs -105.35 (-9.28%)
Day Open	Rs 1,090
Day High	Rs 1,090
Day Low	Rs 1,027.3
Current Volume (BSE)	2,179
BSE Traded Volume	2,179
Combined NSE + BSE Volume	2,179
Turnover	Rs 0.22 crore
Market Capitalisation	Rs 501.2 crore
Market Cap Category	Micro Cap

Jenburkt Pharmaceuticals Ltd. (JENBURPH) traded at Rs 1,030.3. versus the previous close of Rs 1,135.65, a fall of 9.28%. The stock opened at Rs 1,090, reached Rs 1,090, touched Rs 1,027.3. Reported volume was 2,179.

Jenburkt Pharmaceuticals Ltd. (JENBURPH) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 501.2 crore
P/E Ratio	14.43x
P/B Ratio	2.54x
ROE	20.66%
ROCE	26.89%
EPS	Rs 78.71
Dividend Yield	1.82%

Jenburkt Pharmaceuticals Ltd. was valued at a P/E ratio of 14.43x, a P/B ratio of 2.54x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 20.66% and ROCE of 26.89%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 78.71, dividend yield of 1.82%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Jenburkt Pharmaceuticals Ltd. Fundamental Analysis shows a company that is not expensive on the supplied earnings multiple relative to its industry benchmark, while its return ratios appear stronger than the broader Pharmaceuticals & Drugs comparison set. The company’s market capitalisation stands at Rs 501.2 crore, which defines its size but not its quality. On valuation, the stock trades at a P/E ratio of 14.43 and a P/B ratio of 2.54. Those figures give investors two different lenses: earnings valuation through P/E and balance-sheet valuation through P/B.

Jenburkt Pharmaceuticals Ltd. Share Price also carries an earnings per share, or EPS, of 78.71. EPS indicates the earnings attributable to each share, and when compared with the current stock price, it supports the reported P/E ratio of 14.43. The company’s dividend yield is 1.82, which provides historical payout context relative to the current price. Dividend yield is not a promise of future distributions, but it does help investors understand whether the stock has offered some income support in addition to capital market performance.

From a profitability perspective, the company reports ROE of 20.66 and ROCE of 26.89. Those are important in any financial analysis because ROE measures returns generated on shareholder equity, while ROCE captures returns on capital employed across the business. On the supplied numbers, both ratios indicate a business that has been generating relatively healthy returns. In market news, that creates an interesting contrast: a stock can still see a sharp share price decline even when reported profitability ratios look robust.

The P/B ratio of 2.54 suggests the market values the company above its accounting net worth, which is common for profitable businesses, but whether that is high or low needs sector comparison rather than a standalone judgment. That is why Univest views Jenburkt Pharmaceuticals Ltd. Stock Analysis through both valuation and return metrics together. The current session’s price fall has changed the trading picture, but the supplied fundamentals still show a company with positive profitability and a moderate earnings multiple. The next question is how that profile fits within the broader Healthcare and Pharmaceuticals & Drugs universe.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	14.43x
Benchmark Median P/E	25.99x
Benchmark Average P/E	81.5x
Benchmark P/E Range	3.3x to 3,493.04x
Company P/B Ratio	2.54x
Benchmark Median P/B	1.86x
Company ROE	20.66%
Benchmark Median ROE	10.59%
Company ROCE	26.89%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 501.2 crore
Benchmark Median Market Cap	Rs 144.63 crore

Jenburkt Pharmaceuticals Ltd. (JENBURPH) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a P/E ratio of 14.43x, which is below the benchmark median of 25.99x, a difference of -44.48%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a ROE of 20.66%, which is above the benchmark median of 10.59%, a difference of +95.09%. Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a ROCE of 26.89%, which is above the benchmark median of 12.98%, a difference of +107.16%.

Track today’s top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Jenburkt Pharmaceuticals Ltd. Share Price sits within the Healthcare sector and the Pharmaceuticals & Drugs industry, and the sector snapshot adds useful context. Against a same-industry benchmark of 137 companies, the stock’s P/E of 14.43 is below the median of 25.99 and well below the average of 81.5, while still remaining above the industry minimum of 3.3 and far below the maximum of 3493.04.

This sector positioning matters because valuation alone rarely tells the whole story. In the supplied same-industry benchmark, P/E data is available for 104 companies. Jenburkt Pharmaceuticals Ltd.’s P/E ratio of 14.43 is lower than both the median 25.99 and average 81.5. On that basis, the stock looks less richly valued on earnings than much of the benchmark set. The company’s P/B ratio of 2.54 is slightly above the industry average of 2.51 and above the median of 1.86, which suggests the balance-sheet valuation is closer to sector norms than the P/E ratio is.

Profitability comparison is also important. The company’s ROE of 20.66 is higher than the benchmark median of 10.59 and the average of 8.23 across 136 companies. Its ROCE of 26.89 is also above the median of 12.98 and the average of 15.71 across 136 companies. That means the supplied sector data places Jenburkt Pharmaceuticals Ltd. above the benchmark on both key return measures. In other words, the current market decline has happened despite stronger-than-benchmark reported returns.

Size-wise, Jenburkt Pharmaceuticals Ltd. Market Cap of Rs 501.2 crore is just above the benchmark average market capitalisation of Rs 500.48 crore and far above the median of Rs 144.63 crore. Within a market-cap range that runs from Rs 6.16 crore to Rs 3060.41 crore, the company sits near the benchmark average, not at an extreme. Univest therefore sees a nuanced picture: Jenburkt Pharmaceuticals Ltd. Share Price has weakened sharply today, but the industry comparison shows a stock trading on a lower P/E than peers on average, with stronger-than-benchmark ROE and ROCE. That leads naturally to a closer peer check.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,060.41	31.3	0.46	-2.89	-0.26
Hikal Ltd.	HIKAL	2,862.43	0	2.29	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,652.52	40.87	8.32	28.21	26.35
Beta Drugs Ltd.	BETA	2,623.92	67.31	10.65	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,571.92	0	3.06	0	5.36

Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a P/E ratio of 14.43x compared with the displayed peer median of 31.3x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 20.66% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 26.89% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Jenburkt Pharmaceuticals Ltd. (JENBURPH) has a market capitalisation of Rs 501.2 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Jenburkt Pharmaceuticals Ltd. Share Price can be better understood by comparing its valuation and return profile with selected listed peers from the same Pharmaceuticals & Drugs industry. On market capitalisation, Jenburkt Pharmaceuticals Ltd. at Rs 501.2 crore is much smaller than Dishman Carbogen Amcis Ltd. at Rs 3060.41 crore, Hikal Ltd. at Rs 2862.43 crore, Kwality Pharmaceuticals Ltd. at Rs 2652.52 crore, Beta Drugs Ltd. at Rs 2623.92 crore and Hester Biosciences Ltd. at Rs 2072.78 crore. That size gap is worth keeping in mind because smaller companies can show sharper price action.

On valuation, Jenburkt Pharmaceuticals Ltd. trades at a P/E of 14.43, lower than Dishman Carbogen Amcis at 31.3, Kwality Pharmaceuticals at 40.87, Beta Drugs at 67.31, Sai Parenteral’s at 167.74, Fredun Pharmaceuticals at 46.11 and NGL Fine-Chem at 44.1. Among the provided peers with P/E data, only Hester Biosciences at 15.31 is close to Jenburkt Pharmaceuticals Ltd. This indicates that Jenburkt Pharmaceuticals Ltd. Share Price is not carrying the kind of earnings multiple seen in several higher-valued peers.

The P/B ratio of 2.54 places the company above Dishman Carbogen Amcis at 0.46, Hikal at 2.29 and Solara Active Pharma Sciences at 1.93, but below Kwality Pharmaceuticals at 8.32, Beta Drugs at 10.65, Panacea Biotec at 3.06, Sai Parenteral’s at 3.1, Fredun Pharmaceuticals at 6.89, NGL Fine-Chem at 6.45 and Hester Biosciences at 4.58. On returns, ROE of 20.66 is above Hikal, Beta Drugs, Solara, Sai Parenteral’s, Fredun, Hester and far above Dishman and Panacea, though below Kwality Pharmaceuticals at 28.21 and NGL Fine-Chem at 27.9. ROCE of 26.89 is above most listed peers in the supplied set, with NGL Fine-Chem at 33.91 the main exception and Kwality Pharmaceuticals at 26.35 slightly below Jenburkt.

That peer picture suggests Jenburkt Pharmaceuticals Ltd. Stock Performance today does not align with a weak profitability profile. Instead, the market is marking down a smaller Healthcare stock that still screens reasonably on valuation and strongly on return metrics compared with much of its peer group.

Why Investors Are Watching Jenburkt Pharmaceuticals Ltd.

Jenburkt Pharmaceuticals Ltd. Share Price is attracting attention because the stock has moved sharply lower in a single session while still carrying relatively solid reported profitability and a lower P/E ratio than many same-industry peers. That combination often keeps a stock on both trader and investor watchlists, especially when it appears among Top Losers Today in the Indian Stock Market.

• Price action: The stock fell 9.28% to Rs 1030.3 from Rs 1135.65, after opening at Rs 1090 and slipping to an intraday low of Rs 1027.3.
• Trading activity: Total volume was 2,179 shares on BSE, with turnover of Rs 0.22 crore, underlining that the move occurred in a relatively small traded value environment.
• Fundamental context: P/E stands at 14.43, P/B at 2.54, ROE at 20.66, ROCE at 26.89, EPS at 78.71 and dividend yield at 1.82.
• Sector positioning: The company’s P/E is below the industry median and average, while ROE and ROCE are above both the benchmark median and average.
• Peer positioning: Compared with several Pharmaceuticals & Drugs peers, the stock screens lower on P/E and competitive on return ratios.

What investors may monitor next is whether Jenburkt Pharmaceuticals Ltd. Share Price stabilises within its intraday range and how the stock behaves relative to other Healthcare names in market news. Univest also sees importance in tracking whether valuation, return ratios and market-cap positioning continue to look favourable even as near-term selling pressure shapes the stock’s price action.

About Jenburkt Pharmaceuticals Ltd.

Jenburkt Pharmaceuticals Ltd. operates in the Healthcare sector and is classified within the Pharmaceuticals & Drugs industry. Based on the supplied company context, that places it among listed drug and pharmaceutical businesses that are typically assessed through a mix of earnings multiples, return ratios, market capitalisation and industry benchmark comparisons. In the context of Jenburkt Pharmaceuticals Ltd. Share Price, this matters because sector identity often shapes how investors interpret valuation and financial ratios.

The company’s current market capitalisation is Rs 501.2 crore, which places it in the smaller end of the listed Healthcare space even though it is near the industry benchmark average market cap of Rs 500.48 crore. Within the same-industry benchmark of 137 companies, market values span from Rs 6.16 crore to Rs 3060.41 crore, showing that the Pharmaceuticals & Drugs universe includes both very small and relatively larger listed players. Jenburkt Pharmaceuticals Ltd. therefore sits in a broad and diverse peer set.

For readers following Jenburkt Pharmaceuticals Ltd. Latest News, the most relevant business context in the supplied data is that the company is part of an industry where valuation dispersion is wide and profitability varies sharply across peers. That helps explain why investors often look beyond a single trading session and compare P/E, P/B, ROE and ROCE across the sector before judging the significance of a one-day share price fall. Univest uses that comparative approach to place the current stock move within a fuller company and industry framework.

Track Jenburkt Pharmaceuticals Ltd. Share Price on Univest

Use Jenburkt Pharmaceuticals Ltd. (JENBURPH) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Jenburkt Pharmaceuticals Ltd. Share Price can be tracked on Univest for a broader market view beyond a single headline move. Users following Jenburkt Pharmaceuticals Ltd. Share Price Today can monitor live share price trends, 52-week levels, valuation ratios such as P/E and P/B, profitability measures including ROE and ROCE, and the latest Stock Updates in one place. Univest also helps readers compare the stock with listed Healthcare and Pharmaceuticals & Drugs peers, follow shareholding pattern when reported, and place daily market movers in sector context. For investors who want structured Jenburkt Pharmaceuticals Ltd. Stock News and market data, that wider dashboard view can be useful after a sharp session like this one.

Frequently Asked Questions

Why is Jenburkt Pharmaceuticals Ltd. Share Price in focus today?

Ans. Jenburkt Pharmaceuticals Ltd. Share Price is in focus because the stock fell 9.28% to Rs 1030.3 in early trade from the previous close of Rs 1135.65, making it one of the session’s notable top decliners.

What was the latest traded price of Jenburkt Pharmaceuticals Ltd. shares?

Ans. The latest traded price in the supplied snapshot was Rs 1030.3. At that level, Jenburkt Pharmaceuticals Ltd. Share Price was down Rs 105.35 for the day, compared with the previous close of Rs 1135.65.

How much did Jenburkt Pharmaceuticals Ltd. stock fall today?

Ans. The stock declined by Rs 105.35, or 9.28%, in early trade. Jenburkt Pharmaceuticals Ltd. Share Price moved from a previous close of Rs 1135.65 to Rs 1030.3, with the day low recorded at Rs 1027.3.

What were the day open, high and low for Jenburkt Pharmaceuticals Ltd.?

Ans. The stock opened at Rs 1090, touched a day high of Rs 1090 and a day low of Rs 1027.3. This pattern shows Jenburkt Pharmaceuticals Ltd. Share Price opened at its intraday high before moving lower.

What is the market capitalisation of Jenburkt Pharmaceuticals Ltd.?

Ans. Jenburkt Pharmaceuticals Ltd. had a market capitalisation of Rs 501.2 crore in the supplied data. That places the company in the Micro Cap category for this event framework and helps explain the attention on its price action.

What do the valuation ratios of Jenburkt Pharmaceuticals Ltd. show?

Ans. The company trades at a P/E ratio of 14.43 and a P/B ratio of 2.54. Compared with the same-industry benchmark median P/E of 25.99, Jenburkt Pharmaceuticals Ltd. Share Price appears lower valued on earnings.

How profitable is Jenburkt Pharmaceuticals Ltd. based on reported ratios?

Ans. The supplied data shows ROE of 20.66 and ROCE of 26.89. Both are above the same-industry benchmark medians of 10.59 for ROE and 12.98 for ROCE, indicating comparatively stronger reported returns.

What are the EPS and dividend yield of Jenburkt Pharmaceuticals Ltd.?

Ans. Jenburkt Pharmaceuticals Ltd. reported EPS of 78.71 and a dividend yield of 1.82. EPS reflects earnings attributable to each share, while dividend yield shows the historical payout relative to the current market price.

How does Jenburkt Pharmaceuticals Ltd. compare with sector benchmarks?

Ans. Against 137 Pharmaceuticals & Drugs companies, the stock’s P/E of 14.43 is below the median 25.99 and average 81.5. Its ROE of 20.66 and ROCE of 26.89 are above benchmark medians and averages.

Where was the trading volume recorded for Jenburkt Pharmaceuticals Ltd. today?

Ans. The supplied market data shows total volume of 2,179 shares, all recorded on BSE, with turnover of Rs 0.22 crore. That means the visible trading activity in this snapshot came entirely through BSE.